Plazinemdor
 | |
| Clinical data | |
|---|---|
| Other names | CAD-9303; CAD9303 |
| Routes of administration | Oral[1] |
| Drug class | NMDA receptor positive allosteric modulator |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H19ClF2N4O2 |
| Molar mass | 432.86 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Plazinemdor (INN; developmental code name CAD-9303) is an NMDA receptor positive allosteric modulator which is or was under development for the treatment of schizophrenia.[1][2] It is taken orally.[1][2] The drug is intended for treatment of the negative and cognitive symptoms of schizophrenia.[2][3] Plazinemdor was originated by Cadent Therapeutics and is or was under development by Novartis.[1][2] As of April 2023, no recent development has been reported for schizophrenia.[1][2]
See also
References
- 1 2 3 4 5 "Plazinemdor". AdisInsight. 28 April 2023. Retrieved 5 June 2026.
- 1 2 3 4 5 Ye N, Wang Q, Li Y, Zhen X (March 2025). "Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities". Medicinal Research Reviews. 45 (2): 755–787. doi:10.1002/med.22086. PMID 39300769.
Cadent Therapeutics developed plazinemdor (CAD‐9303; Figure 9), an oral NMDA receptor PAM, to target cognitive deficits and negative symptoms in patients with schizophrenia.76 In 2021, a phase 1 clinical trial (NCT04306146) was conducted to assess its safety and tolerability among patients with schizophrenia and healthy volunteers; however, no results have been reported thus far.
- ↑ Piser T, Anderson D, Bettini E, Bureau M, Capuani C, Christian E, et al. (December 2019). "NMDA Receptor Positive Allosteric Modulator CAD-9303 Reverses Mismatch Negativity and Behavioral Impairments in Pharmacological Models of NMDA Receptor Hypofunction". Neuropsychopharmacology. 44 (Suppl 1): 350–350.